Blueprint Medicines Corp
BPMC94.725USD
+5.225+5.84%
Horário de mercado （ET）Cotações atrasadas em 15 min
6.04BValor de mercado
PerdaP/L TTM
Mais detalhes de Blueprint Medicines Corp Empresa
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Informações da empresa
Código da empresaBPMC
Nome da EmpresaBlueprint Medicines Corp
Data de listagemApr 30, 2015
Fundado em2008
CEOMs. Kathryn D (Kate) Haviland
Número de funcionários649
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 30
Endereço45 Sidney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139
Telefone16173747580
Sitehttps://www.blueprintmedicines.com/
Código da empresaBPMC
Data de listagemApr 30, 2015
Fundado em2008
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Dr. Christopher K. Murray, Ph.D.
Dr. Christopher K. Murray, Ph.D.
Executive Vice President, Chief Technical Operations and Quality Officer
Executive Vice President, Chief Technical Operations and Quality Officer
28.60K
+48.63%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
23.94K
-13.94%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.09K
+56.18%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
+19.95%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
+4.75%
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Acionista
Tempo de atualização: dom, 23 de fev
Tempo de atualização: dom, 23 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Estatísticas dos acionistas
Acionista
Proporção
The Vanguard Group, Inc.
10.47%
T. Rowe Price Associates, Inc.
8.70%
BlackRock Institutional Trust Company, N.A.
7.74%
Wellington Management Company, LLP
6.63%
State Street Global Advisors (US)
3.87%
Other
62.58%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
49.33%
Investment Advisor
40.93%
Hedge Fund
10.05%
Research Firm
2.72%
Sovereign Wealth Fund
1.10%
Individual Investor
1.08%
Venture Capital
1.04%
Pension Fund
0.55%
Bank and Trust
0.45%
Participação acionária institucional
Tempo de atualização: seg, 24 de fev
Tempo de atualização: seg, 24 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
658
69.72M
107.98%
-1.29M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.69M
2.64%
-1.98M
-53.96%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
Macquarie Investment Management
1.26M
1.97%
-4.68K
-0.37%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Invesco Biotechnology & Genome ETF
2.8%
WisdomTree BioRevolution Fund
2.56%
Tema Oncology ETF
2.52%
Range Cancer Immunotherapy ETF
1.97%
SPDR S&P Biotech ETF
1.82%
Virtus LifeSci Biotech Products ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
American Century Focused Dynamic Growth ETF
1.02%
iShares Health Innovation Active ETF
0.88%
JPMorgan Fundamental Data Science Small Core ETF
0.88%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção2.8%
WisdomTree BioRevolution Fund
Proporção2.56%
Tema Oncology ETF
Proporção2.52%
Range Cancer Immunotherapy ETF
Proporção1.97%
SPDR S&P Biotech ETF
Proporção1.82%
Virtus LifeSci Biotech Products ETF
Proporção1.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.16%
American Century Focused Dynamic Growth ETF
Proporção1.02%
iShares Health Innovation Active ETF
Proporção0.88%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.88%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados